Get the Stockscreener App
4.285
2.27%
0.095
After Hours:
4.29
0.005
+0.12%
Arbutus Biopharma Corp stock is traded at $4.285, with a volume of 1.89M.
It is up +2.27% in the last 24 hours and down -15.32% over the past month.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
See More
Previous Close:
$4.19
Open:
$4.23
24h Volume:
1.89M
Relative Volume:
0.31
Market Cap:
$848.88M
Revenue:
$191.45M
Net Income/Loss:
$160.72M
P/E Ratio:
5.2097
EPS:
0.8225
Net Cash Flow:
$-34.44M
1W Performance:
+2.51%
1M Performance:
-15.32%
6M Performance:
-4.35%
1Y Performance:
-4.14%
1-Day Range:
$4.215
$4.30
1-Week Range:
$4.05
$4.30
52-Week Range:
$3.50
$5.45
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Name
Arbutus Biopharma Corp
Sector
Industry
Phone
604-419-3200
Address
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.285 | 848.88M | 191.45M | 160.72M | -34.44M | 0.8225 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-22 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Initiated | Jefferies | Hold |
| Dec-17-20 | Initiated | H.C. Wainwright | Buy |
| Jul-27-20 | Resumed | JMP Securities | Mkt Outperform |
| Jul-24-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-19-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-06-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-20-20 | Initiated | Robert W. Baird | Outperform |
| Feb-05-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Oct-07-19 | Reiterated | B. Riley FBR | Buy |
| Oct-04-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-16-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-15-18 | Upgrade | Wedbush | Underperform → Neutral |
| Oct-12-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-06-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Mar-19-18 | Resumed | Chardan Capital Markets | Buy |
| Mar-19-18 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-04-17 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-01-17 | Reiterated | Wedbush | Outperform |
| Dec-13-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-30-16 | Upgrade | Chardan Capital Markets | Neutral → Buy |
View All
Arbutus Biopharma Corp Stock (ABUS) Latest News
Form 13D/A Arbutus Biopharma Corp For: 5 October By Investing.com - Investing.com UK
At $5 a share, Arbutus Biopharma (ABUS) accepts tendered shares; Roivant retains about 19.5%. - Stock Titan
The share offer capped at $230M has expired. Arbutus (ABUS) announces final results. - Stock Titan
About 23% of Arbutus shares are being bought back for $230 million. - Stock Titan
Arbutus gains on plans to buy back 46M shares in tender offer - TradingView
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer - GlobeNewswire
Form 4 Arbutus Biopharma Corp For: 23 September By Investing.com - Investing.com Canada
Q32 Bio (Nasdaq:QTTB)Stock Analysis - simplywall.st
Arbutus Biopharma Stock Price Forecast. Should You Buy ABUS? - StockInvest.us
ABUS Stock Price, Quote & Chart - ChartMill
An 8% holder now reports a passive stake in Arbutus Biopharma (ABUS) - Stock Titan
Arbutus Biopharma Corp (ABUS) Peer Comparison – Compare with Others - Value Research
Arbutus Biopharma (ABUS) Edges Up to $5.12, Stuck Between $4.86 Support and $5.38 ResistanceVolatility Term Structure - careplusvn.com
Arbutus Biopharma Corp (ABUS) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Quantum BioPharma Ltd Peer Comparison – Compare with Others - Value Research
Cronos Group Inc. Common Share (CRON) Peer Comparison – Compare with Others - Value Research
Acasti Pharma Inc. Class AADR Peer Comparison – Compare with Others - Value Research
Arbutus Biopharma Corp (ABUS) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Arbutus Biopharma Launches Modified Dutch Auction Tender Offer to Repurchase Up to US$230 Million of Common Shares - Quiver Quantitative
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share - Yahoo Finance
Arbutus Commences US$230 Million Modified “Dutch - GlobeNewswire
Arbutus Biopharma Launches $230 Million Tender Offer for Common Shares - Yahoo Finance
Arbutus Biopharma Launches Modified Dutch Auction Tender Offer to Repurchase Up to US$230 Million of Common Shares - Quiver Quantitative
Arbutus Biopharma (NASDAQ:ABUS) Capital Strategy Draws Attention - Kalkine Media
Why Is Arbutus Biopharma Stock Gaining Friday? - TradingView
ABUS Stock Pops As Moderna Settlement Transforms Balance Sheet - StocksToTrade
Arbutus Biopharma Announces $230 Million Modified Dutch Auction Tender Offer for Shares - Kalkine Media
Why is Arbutus Biopharma stock surging today? - Investing.com India
Why is Arbutus Biopharma stock surging today? - Investing.com
Why is Arbutus Biopharma stock surging today? By Investing.com - Investing.com UK
Arbutus Biopharma shares jump after unveiling $230 million share buyback plan - Yahoo Finance
ABUS Stock Surges 10% Today — What’s Driving This Super Rally? - Stocktwits
ABUS Stock Surges 10% Today — What’s Driving This Super Rally? - Yahoo Finance
ABUS Looks 90.4% Undervalued on GF Value™ Despite Possible Value Trap - GuruFocus
Arbutus Biopharma stock surges on $230M buyback plan - Investing.com
Arbutus (NASDAQ: ABUS) plans Dutch auction share buyback - Stock Titan
ABUS Looks 90.4% Undervalued on GF Value™ - GuruFocus
Arbutus Biopharma Announces Plans for Up to $230 Million Modified Dutch Auction Tender Offer - Quiver Quantitative
Arbutus Announces Intent to Repurchase Up to US$230 Million - GlobeNewswire
Arbutus Biopharma Corporation announces an Equity Buyback for $230 million worth of its shares. - marketscreener.com
Arbutus Gains on $230m Buyback Using Moderna Settlement Proceeds - Bloomberg.com
ABUS Stock Surges 10% Today — What’s Driving This Super Rally? - TradingView
Moderna, Arbutus Clash On Gov't Venue For Vax IP Claims - Law360
Arbutus Plans $230 Million Share Buyback After Moderna Deal - MyChesCo
Arbutus Biopharma (NASDAQ:ABUS) Cut to Hold at Wall Street Zen - MarketBeat
ABUS|Arbutus Biopharma Corp|Price:4.710|Chg%:+0.130 - TradingKey
Arbutus Biopharma (ABUS) Stock Profit Surge Leaves Durability Questions Open - simplywall.st
Morgan Stanley (ABUS) units report near-9% Arbutus Biopharma stake in 13G/A filing - stocktitan.net
Arbutus Biopharma earnings matched, revenue topped estimates By Investing.com - Investing.com Nigeria
Arbutus Biopharma (NASDAQ:ABUS) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Arbutus Biopharma Corp Stock (ABUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arbutus Biopharma Corp Stock (ABUS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nguyen Tuan | Chief Financial Officer |
Sep 18 '26 |
Option Exercise |
3.57 |
293,100 |
1,047,646 |
366,600 |
| Sawhney Roger | Director |
Sep 18 '26 |
Option Exercise |
3.88 |
131,333 |
509,572 |
131,333 |
| Beardsley Robert A | Director |
Sep 18 '26 |
Option Exercise |
3.82 |
131,333 |
502,218 |
131,333 |
2.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):